Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697024 | 0.71 | MAPT (0.54) | CASP3CA12CA9MAPTKMT2A | |
| SCHEMBL864950 | 0.71 | KIF11 (0.46) | — | |
| SCHEMBL864206 | 0.71 | APOBEC3G (0.55) | TSHR | |
| SCHEMBL7987177 | 0.67 | CASP3 (0.49) | CASP3CA12CA9KMT2AALDH1A1 | |
| SCHEMBL10304923 | 0.67 | PTGS1 (0.65) | CASP3CA12CA9MAPTKMT2A | |
| SCHEMBL6095022 | 0.67 | TYR (0.64) | CASP3CA12CA9KMT2AALDH1A1 | |
| SCHEMBL10339317 | 0.67 | TYR (0.64) | CASP3CA12CA9MAPTKMT2A | |
| SCHEMBL7518302 | 0.67 | CASP3 (0.49) | CASP3CA12CA9KMT2AALDH1A1 | |
| SCHEMBL17866115 | 0.67 | CASP3 (0.53) | CASP3CA12CA9MAPTKMT2A | |
| SCHEMBL15624560 | 0.67 | MPO (0.50) | CASP3CA12CA9MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398777-B1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMA SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| EP-2398777-B1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMA SPA (IT) | 2013-08-14 | — | — | EP | disclosed |
| US-8450314-B2 | Pyrimidopyridazine derivatives useful as P38 MAPK inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-28 | — | — | US | disclosed |
| US-8450314-B2 | Pyrimidopyridazine derivatives useful as P38 MAPK inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-28 | — | — | US | disclosed |
| US-8450314-B2 | Pyrimidopyridazine derivatives useful as P38 MAPK inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-05-28 | — | — | US | disclosed |
| US-20120077809-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-03-29 | — | — | US | disclosed |
| US-20120077809-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-03-29 | — | — | US | disclosed |
| EP-2398777-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | CHIESI FARMACEUTICI S.p.A. (IT) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010094955-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010094955-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077809-A1 | PYRIMIDOPYRIDAZINE DERIVATIVES USEFUL AS P38 MAPK INHIBITORS | MAPK1, MAPK4, MAPK7 | CASP3 1916/4885CA12 4874/4885CA9 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.